Oncology and Hematology - MedEd On The Go

49-64 of 75

Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
MinuteCE®
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
Carey Anders, MD, FASCO
1.00 program credit
- Carey Anders, MD, FASCO
1.00 program credit
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
MinuteCE®
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
Sarah Sammons, MD
1.00 program credit
- Sarah Sammons, MD
1.00 program credit
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
MinuteCE®
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
Carey Anders, MD, FASCO; Sarah Sammons, MD
1.00 program credit
- Carey Anders, MD, FASCO
- Sarah Sammons, MD
1.00 program credit
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
MinuteCE®
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
Carey Anders, MD, FASCO; Sarah Sammons, MD
1.00 program credit
- Carey Anders, MD, FASCO
- Sarah Sammons, MD
1.00 program credit
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
MinuteCE®
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
Sarah Sammons, MD
1.00 program credit
- Sarah Sammons, MD
1.00 program credit
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
MinuteCE®
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Sarah Sammons, MD; Carey Anders, MD, FASCO
1.00 program credit
- Sarah Sammons, MD
- Carey Anders, MD, FASCO
1.00 program credit
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
CME/CE
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
Heather McArthur, MD; Margaret Gatti-Mays, MD, MPH
0.25 credits
- Heather McArthur, MD
- Margaret Gatti-Mays, MD, MPH
0.25 credits
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD; Helena Yu, MD
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Helena Yu, MD; Pasi Antero Jänne, MD, PhD
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Helena Yu, MD; Pasi Antero Jänne, MD, PhD
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
MinuteCE®
HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI and Platinum-Based Chemotherapy
Pasi Antero Jänne, MD, PhD; Helena Yu, MD
0.75 credits 6 episodes
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 credits 6 episodes
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Pasi Antero Jänne, MD, PhD
0.75 program credits
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD; Helena Yu, MD
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Overcoming EGFR Resistance With HER3-Directed ADCs
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®
Overcoming EGFR Resistance With HER3-Directed ADCs
Helena Yu, MD
0.75 program credits
- Helena Yu, MD
0.75 program credits
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
CME/CE
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
Brian Slomovitz, MD; Robert L. Coleman, MD, FACOG, FACS
0.25 credits
- Brian Slomovitz, MD
- Robert L. Coleman, MD, FACOG, FACS
0.25 credits
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Broadcast Replay
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Nataliya Uboha, MD, PhD
0.75 credits
- Nataliya Uboha, MD, PhD
0.75 credits

4/5